Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a ...
This week - the enterprise has a newfound obsession with "quality data" - but are we on the wrong track for AI? Pega and HubSpot turn in strong earnings, but Wall Street's AI fever (dreams?) persist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results